Despite advances, chronic kidney disease, including end stage renal disease requiring renal replacement therapy remains one of the commonest causes of morbidity and mortality.
Chronic kidney disease, including end stage renal disease and amongst the most expensive health care problems in the United States. The overall prevalence of CKD in the general population is approximately 14 percent.
More than 661,000 Americans have kidney failure. Of these, 468,000 individuals are on dialysis, and roughly 193,000 live with a functioning kidney transplant.
The adjusted incidence rate of ESRD in the United States rose sharply in the 1980s and 1990s, leveled off in the early 2000s, and has declined slightly since its peak in 2006.
Solving chronic kidney disease can benefit greatly through regenerative medicine and bioengineering techniques. This committee is helping to identify specific challenges that need to be overcome, exploring enabling technologies that may help accelerate solutions to these challenges for CKD, and coordinating innovative research collaborations to provide bioengineered solutions to kidney failure.
Please log in again. The login page will open in a new tab. After logging in you can close it and return to this page.